相关实验视频

Updated: Jun 4, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

用Rabdosiin准METTL8克服了肝细胞癌中伦瓦提尼布耐药性的作用

Yunpeng Liu¹, Muhua Chen², Xiang-Xu Wang¹

¹The Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, 710032, Xi'an, PR China; Innovation Research Institute, Xijing Hospital, Air Force Medical University, 710032, Xi'an, PR China.

Experimental cell research

|December 19, 2024

概括

这项研究确定METTL8是肝细胞癌 (HCC) 伦瓦提尼布耐药性的关键驱动因素. 用Rabdosiin针对METTL8可以克服耐药性并恢复对lenvatinib治疗的敏感性.

科学领域:

肝细胞癌研究肝细胞癌研究
分子瘤学分子瘤学
药物耐药性机制药物耐药性机制

背景情况:

伦瓦提尼布是晚期肝细胞癌 (HCC) 的重要一线治疗方法,改善了一些患者的生存率.
对伦瓦提尼布的耐药性构成了重大的临床挑战,限制了其长期疗效.
识别耐药性的分子驱动因素对于开发克服治疗失败的策略至关重要.

研究的目的:

确定导致HCC. lenvatinib耐药性的关键分子因素.
探索克服伦瓦提尼布耐药性的治疗策略.
评估METTL8作为伦瓦替尼治疗的潜在治疗标和生物标志物.

主要方法:

全基因组的CRISPR-Cas9激活屏幕用于识别与耐药性相关的基因.
在体外和体内测试以验证METTL8.8的作用.
免疫组织化学染色以将METTL8表达与患者组织中伦瓦提尼布敏感度相关联.
自然化合物库查和虚拟药物查以识别METTL8抑制剂.

主要成果:

METTL8被确定为一个关键的基因,在HCC中调解伦瓦提尼布耐药性.
在抗伦瓦替尼布的HCC细胞中观察到METTL8表达的升高,并且与患者样本中伦瓦替尼布敏感度的降低相关.
拉布多西因是一种天然化合物,被确定为METTL8抑制剂,并且在克服METTL8介导的伦瓦替尼抗性方面表现出有效性.

结论:

METTL8是一种新的治疗点,用于克服HCC. lenvatinib耐药性.
向METTL8可能会恢复lenvatinib的敏感性,从而改善治疗结果.
METTL8作为一个有价值的生物标志物,用于预测HCC患者的伦瓦提尼布反应.

关键词:

肝细胞癌是肝细胞癌.伦瓦提尼布 (Lenvatinib) 是一种药物.在METTL8中,使用的是METTL8.电阻电阻电阻电阻电阻电阻

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...